Low-dose weekly decitabine and venetoclax in TP53 -mutated myeloid malignancies
Shapiro, Lauren C, Mantzaris, Ioannis, Shastri, Aditi, Sica, Alejandro R., Bachier-Rodriguez, Lizamarie, Kornblum, Noah, Gritsman, Kira, Feldman, Eric Jay, Verma, Amit K., Braunschweig, Ira, Saunthararajah, Yogen, Goldfinger, Mendel
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Renal impairment impact on CPX-351 pharmacokinetics and safety
Lancet, Jeffrey E., Feldman, Eric Jay, Kolitz, Jonathan E., Pentikis, Helen S, Mayer, Lawrence, Louie, Arthur Chin
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy
Feldman, Eric Jay, Lancet, Jeffrey E., Kolitz, Jonathan E., Hogge, Donna, Tallman, Martin S., Goldberg, Stuart L., Kovacsovics, Tibor, Louie, Arthur Chin, Cortes, Jorge E.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigator’s choice—A subset analysis by prognostic group
Goldberg, Stuart, Cortes, Jorge E., Feldman, Eric Jay, Rizzieri, David, Kantarjian, Hagop, Limor, Sora, Louie, Arthur Chin, Kolitz, Jonathan E.
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
A comparison of CR versus CRi response following CPX-351 treatment of newly diagnosed AML in elderly patients (pts)
Lancet, Jeffrey E., Cortes, Jorge E., Kovacsovics, Tibor, Hogge, Donna, Kolitz, Jonathan E., Tallman, Martin S., Chiarella, Michael, Louie, Arthur Chin, Feldman, Eric Jay
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)
Griffiths, Elizabeth A., Kantarjian, Hagop M., Roboz, Gail J., Kropf, Patricia Lamont, O'Connell, Casey Lee, Yee, Karen W. L., Garcia-Manero, Guillermo, Jabbour, Elias, Feldman, Eric Jay, Walsh, Katherine Jean, Rizzieri, David, Stock, Wendy, Lunin, Scott D., Naim, Sue, Choy, Gavin S., Taverna, Pietro, Hao, Yong, Azab, Mohammad, Chung, Woonbok, Issa, Jean-Pierre J.
Published in Journal of clinical oncology (20.05.2014)
Published in Journal of clinical oncology (20.05.2014)
Get full text
Journal Article
VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia
Ravandi, Farhad, Ritchie, Ellen K., Sayar, Hamid, Strickland, Stephen Anthony, Craig, Michael, Selleslag, Dominik L. D., Maertens, Johan, Havelange, Violaine, Lancet, Jeffrey E., Ketchum, Steven B, Acton, Gary, Mehta, Cyrus R., Silva, Eric, Craig, Adam, Fox, Judith Ann, Stuart, Robert K., Erba, Harry Paul, Vey, Norbert, Schiller, Gary J., Feldman, Eric Jay
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article